Key result
Vigabatrin at therapeutic and supratherapeutic doses did not prolong the QTc interval, with all 1-sided upper 95% CIs for the difference from placebo being <10 ms.
Why the study?
Does vigabatrin prolong the QTc interval in healthy participants?
RCT
Double-blind
4-sequence crossover
No
Does vigabatrin prolong the QTc interval in healthy participants?
Vigabatrin at therapeutic and supratherapeutic doses does not prolong the QTc interval in healthy volunteers, confirming a lack of proarrhythmic potential.
Answers are grounded in this paper and cite their sources.
Vigabatrin shows no QTc prolongation; confirms cardiac safety and supports unrestricted clinical use in epilepsy without arrhythmia monitoring.
PURPOSE: A thorough QT study was performed to assess the proarrhythmic potential of vigabatrin, an antiepileptic drug approved in the United States for the treatment of infantile spasms and refractory complex partial seizures. METHODS: In this Phase I, randomized, double-blind, placebo- and active-controlled (moxifloxacin), 4-sequence, crossover study conducted at a single center, healthy participants received 1 of 4 randomly assigned treatments: 3.0g vigabatrin solution (therapeutic dose) and 1 moxifloxacin placebo tablet; 6.0g vigabatrin solution (supratherapeutic dose) and 1 moxifloxacin placebo tablet; 400 mg moxifloxacin and vigabatrin placebo solution; moxifloxacin placebo tablet and vigabatrin placebo solution. FINDINGS: Mean changes from baseline in placebo-corrected QTcF, QTcB, and QTcI with vigabatrin 3.0 g and 6.0 g indicated no signal for any QTc effect relative to baseline. All 1-sided upper 95% confidence intervals for the differences between each vigabatrin dose and placebo were <10 ms at all time points. QTcF was unaffected by increasing plasma vigabatrin concentrations; no arrhythmias were observed in any treatment group. Low rates of first-degree atrioventricular block, sinus tachycardia, and sinus bradycardia occurred in all treatment groups. Most adverse events were mild. IMPLICATIONS: The findings from this thorough QT study are consistent with existing clinical data and confirm a lack of proarrhythmic potential of vigabatrin.
No takes yet. Share an insight, caveat, or question.
Tolbert et al. (2017) conducted an RCT in Healthy volunteers. Vigabatrin vs. Placebo and moxifloxacin was evaluated on Mean changes from baseline in placebo-corrected QTcF, QTcB, and QTcI. Vigabatrin at therapeutic and supratherapeutic doses did not prolong the QTc interval, with all 1-sided upper 95% CIs for the difference from placebo being <10 ms.
Synapse has enriched 10 related papers. Consider them for comparative context: